Recommendations on the treatment of metastatic hormone-sensitive prostate cancer: Patient selection

Abstract

The standard treatment for metastatic hormone-sensitive prostate cancer (mHSPC) is now a combination of androgen deprivation therapy plus an androgen receptor-targeted therapy (abiraterone, apalutamide, enzalutamide or darolutamide), with or without chemotherapy (docetaxel). The selection of suitable patients for each therapeutic approach has become a determining factor to ensure efficacy and minimize side effects. This article combines recent clinical evidence with the accumulated experience of experts in medical oncology, radiation oncology and urology, to provide a comprehensive view and therapeutic recommendations for mHSPC.

Keywords: Carcinoma de próstata hormonosensible metastásico; Carga tumoral; Doblete; Doublet; Metastatic hormone-sensitive prostate carcinoma; Radioterapia; Radiotherapy; Triplet; Triplete; Tumor burden.